森下仁丹の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/11/10 | 1,955 | 1,955 | 1,911 | 1,911 | -18 | -0.9% | 3,300 |
| 2022/11/09 | 1,926 | 1,929 | 1,910 | 1,929 | +8 | +0.4% | 4,400 |
| 2022/11/08 | 1,910 | 1,987 | 1,907 | 1,921 | +8 | +0.4% | 7,100 |
| 2022/11/07 | 1,910 | 1,915 | 1,910 | 1,913 | +3 | +0.2% | 1,300 |
| 2022/11/04 | 1,910 | 1,910 | 1,910 | 1,910 | ±0 | ±0% | 1,600 |
| 2022/11/02 | 1,916 | 1,916 | 1,910 | 1,910 | +5 | +0.3% | 600 |
| 2022/11/01 | 1,905 | 1,905 | 1,905 | 1,905 | ±0 | ±0% | 700 |
| 2022/10/31 | 1,905 | 1,905 | 1,905 | 1,905 | ±0 | ±0% | 300 |
| 2022/10/28 | 1,915 | 1,915 | 1,905 | 1,905 | -10 | -0.5% | 200 |
| 2022/10/27 | 1,914 | 1,915 | 1,910 | 1,915 | +10 | +0.5% | 1,100 |
| 2022/10/26 | 1,910 | 1,910 | 1,905 | 1,905 | -7 | -0.4% | 200 |
| 2022/10/25 | 1,909 | 1,912 | 1,908 | 1,912 | +12 | +0.6% | 1,300 |
| 2022/10/24 | 1,900 | 1,900 | 1,900 | 1,900 | ±0 | ±0% | 500 |
| 2022/10/21 | 1,902 | 1,902 | 1,900 | 1,900 | ±0 | ±0% | 1,400 |
| 2022/10/20 | 1,900 | 1,900 | 1,900 | 1,900 | +5 | +0.3% | 200 |
| 2022/10/19 | 1,894 | 1,900 | 1,885 | 1,895 | -1 | -0.1% | 1,800 |
| 2022/10/18 | 1,891 | 1,900 | 1,880 | 1,896 | +15 | +0.8% | 2,000 |
| 2022/10/17 | 1,889 | 1,891 | 1,881 | 1,881 | -1 | -0.1% | 1,100 |
| 2022/10/14 | 1,881 | 1,882 | 1,881 | 1,882 | +1 | +0.1% | 200 |
| 2022/10/13 | 1,884 | 1,884 | 1,881 | 1,881 | -3 | -0.2% | 300 |
| 2022/10/12 | 1,883 | 1,898 | 1,883 | 1,884 | -4 | -0.2% | 600 |
| 2022/10/11 | 1,888 | 1,888 | 1,888 | 1,888 | +6 | +0.3% | 100 |
| 2022/10/07 | 1,883 | 1,883 | 1,882 | 1,882 | -6 | -0.3% | 200 |
| 2022/10/06 | 1,888 | 1,888 | 1,888 | 1,888 | ±0 | ±0% | 200 |
| 2022/10/05 | 1,882 | 1,888 | 1,882 | 1,888 | -9 | -0.5% | 300 |
| 2022/10/04 | 1,897 | 1,897 | 1,897 | 1,897 | +16 | +0.9% | 100 |
| 2022/10/03 | 1,886 | 1,886 | 1,881 | 1,881 | - | - | 400 |
| 2022/09/30 | 0 | 0 | 0 | 0 | - | - | 0 |
| 2022/09/29 | 1,900 | 1,900 | 1,883 | 1,883 | -17 | -0.9% | 200 |
| 2022/09/28 | 1,888 | 1,900 | 1,888 | 1,900 | +12 | +0.6% | 300 |
| 2022/09/27 | 1,889 | 1,889 | 1,887 | 1,888 | -1 | -0.1% | 500 |
| 2022/09/26 | 1,902 | 1,903 | 1,887 | 1,889 | +1 | +0.1% | 1,600 |
| 2022/09/22 | 1,891 | 1,891 | 1,888 | 1,888 | -3 | -0.2% | 900 |
| 2022/09/21 | 1,900 | 1,900 | 1,889 | 1,891 | -9 | -0.5% | 600 |
| 2022/09/20 | 1,888 | 1,900 | 1,888 | 1,900 | -3 | -0.2% | 600 |
| 2022/09/16 | 1,903 | 1,903 | 1,903 | 1,903 | ±0 | ±0% | 100 |
| 2022/09/15 | 1,903 | 1,903 | 1,903 | 1,903 | ±0 | ±0% | 300 |
| 2022/09/14 | 1,891 | 1,903 | 1,887 | 1,903 | +3 | +0.2% | 500 |
| 2022/09/13 | 1,887 | 1,900 | 1,887 | 1,900 | +13 | +0.7% | 900 |
| 2022/09/12 | 1,902 | 1,902 | 1,887 | 1,887 | -4 | -0.2% | 900 |
| 2022/09/09 | 1,894 | 1,895 | 1,890 | 1,891 | -4 | -0.2% | 1,300 |
| 2022/09/08 | 1,900 | 1,900 | 1,895 | 1,895 | -5 | -0.3% | 1,000 |
| 2022/09/07 | 1,904 | 1,904 | 1,898 | 1,900 | -2 | -0.1% | 800 |
| 2022/09/06 | 1,901 | 1,909 | 1,901 | 1,902 | +1 | +0.1% | 800 |
| 2022/09/05 | 1,900 | 1,910 | 1,900 | 1,901 | +1 | +0.1% | 600 |
| 2022/09/02 | 1,901 | 1,908 | 1,900 | 1,900 | -1 | -0.1% | 600 |
| 2022/09/01 | 1,908 | 1,908 | 1,901 | 1,901 | -8 | -0.4% | 1,100 |
| 2022/08/31 | 1,903 | 1,910 | 1,902 | 1,909 | +6 | +0.3% | 900 |
| 2022/08/30 | 1,904 | 1,904 | 1,903 | 1,903 | ±0 | ±0% | 400 |
| 2022/08/29 | 1,905 | 1,916 | 1,902 | 1,903 | -2 | -0.1% | 900 |
501～
550
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「仁 丹」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 仁 丹 | 211,400円 | +2.4% | +10.4% | 2.60% | 12.36倍 | 0.69倍 |
|
代名詞の仁丹から整腸作用軸に健康サプリ、医薬品へ展開。シームレスカプセル技術に特長 |
| ラクオリア | 46,200円 | +138.6% | - | 0.00% | 42.35倍 | 1.78倍 |
|
ファイザー旧国内研究所が前身。導出した発売済み消化器薬等収益柱に成長、低分子創薬に強い |
| モダリス | 14,100円 | - | - | 0.00% | - | 8.93倍 |
|
遺伝子治療薬の創薬ベンチャー、切断しない独自のゲノム編集技術に強み。研究開発中心は米国 |
| ＯＴＳ | 3,200円 | +63.9% | - | 0.00% | - | 9.38倍 |
|
がん治療ワクチン創薬ベンチャー。大手製薬と開発提携。東大医科研発。会社計画は非開示 |
| ケイファーマ | 73,000円 | -100.0% | - | 0.00% | - | 3.16倍 |
|
慶応大学発医療ベンチャー。ｉＰＳ細胞による再生医療と創薬の２本柱。中枢神経系が得意領域 |
市場注目の銘柄
チャート関連のコラム
